Tumor Lysis Syndrome in Patients with Hematological Malignancies

Table 1

Patients risk classification in HMs.

Risk group	Type of HMs
High risk	(i) Advanced stage Burkitt’s lymphoma/leukemia (B-ALL)
	(ii) Lymphoblastic lymphoma with LDH ≥ 2 × ULN
	(iii) Early stage Burkitt’s lymphoma/leukemia with LDH ≥ 2 × ULN
	(iv) ALL with WBC count ≥ /L or less if the baseline elevation of LDH is twice ULN; (v) AML with WBC count ≥/L
	(vi) Diffuse large B-cell lymphoma (DLBCL) with an elevated baseline LDH of twice ULN, and bulky disease
Intermediate risk	(i) AML with a WBC between /l and /l or <25 × 10^9/L if the baseline elevation of LDH is twice ULN
	(ii) ALL with WBC < /L and an LDH of less than twice ULN
	(iii) Early stage Burkitt lymphoma/leukemia with an LDH of less than twice ULN
	(iv) DLBCL with a baseline increase in LDH of twice ULN but nonbulky disease
	(v) CLL with WBC ≥ /L
Low risk	(i) Indolent lymphomas
	(ii) CLL
	(iii) Chronic myelogenous leukemia (CML)
	(iv) AML with WBC count < /L and an LDH elevated to less than twice ULN
	(v) MM

Source. Customized from recommendations for the evaluation of risk and prophylaxis of tumor lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. BJH, Cairo MS et al. 149, 578–586, copyright 2010 Blackwell Publishing Ltd.